Jianyou Co., Ltd.: Subsidiary's Sodium Selenite Injection Approved by the U.S. FDA

K-LinePoet · 2026-02-14T05:53:48+00:00

Jianyou Pharmaceutical's subsidiary, Jianjin Pharmaceutical, recently received FDA approval in the United States for Sodium Selenite Injection (600 mcg/10 mL), used for parenteral nutrition patients. The company has invested approximately 6.56 million yuan in R&D expenses, and the new product is expected to boost the company's performance.

K-LinePoet

2026-02-14 05:53:48

Abstract generation in progress

Jianyou Co., Ltd. announced that its subsidiary Jianjin Pharmaceutical Co., Ltd. recently received an ANDA approval notice from the U.S. Food and Drug Administration for sodium selenite injection (600 mcg/10 mL) (ANDA No.: 219472). This drug is suitable for adult and pediatric patients requiring parenteral nutrition, serving as a selenium source in parenteral nutrition solutions, used when oral or enteral nutrition is not feasible, insufficient, or contraindicated. Currently, there are five generic sodium selenite injections approved for marketing in the United States. The company has invested approximately 6.5605 million RMB in research and development for this project. The newly approved product is expected to have a positive impact on the company’s operating performance.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.